MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
31.38
-0.23
-0.73%
After Hours: 31.38 0 0.00% 19:41 12/04 EST
OPEN
31.54
PREV CLOSE
31.61
HIGH
32.26
LOW
31.35
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
46.48
52 WEEK LOW
25.28
MARKET CAP
4.98B
P/E (TTM)
11.30
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TGTX last week (1124-1128)?
Weekly Report · 3d ago
TG Therapeutics CEO to Join Evercore Healthcare Conference Fireside Chat
Reuters · 6d ago
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Barchart · 6d ago
TG Therapeutics TGTX Q3 2025 Earnings Transcript
NASDAQ · 11/27 22:53
Director Yann Echelard Reports Sale of TG Therapeutics Common Shares
Reuters · 11/25 22:32
Weekly Report: what happened at TGTX last week (1117-1121)?
Weekly Report · 11/24 10:26
Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap
Seeking Alpha · 11/21 16:03
TG Therapeutics: Concerns About Slowing Growth And New Competition
Seeking Alpha · 11/18 22:23
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.